RMR Wealth Builders’s CASI Pharmaceuticals CASI Stock Holding History

RMR Wealth Builders’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	–	–	253
2021 Q1	$0	Buy	+2	New	+$56	﹤0.01%	788

Other funds holding CASI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RMR Wealth Builders's CASI Position: Q2 2021 in Review

RMR Wealth Builders sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 2 shares.

RMR Wealth Builders first reported a position in CASI in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

RMR Wealth Builders reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
RMR Wealth Builders sold 2 CASI Pharmaceuticals shares in Q2 2021.
RMR Wealth Builders first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 1 quarter.
RMR Wealth Builders's CASI Pharmaceuticals position peaked at $0 in Q1 2021.
68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on RMR Wealth Builders's 13F filing for Q2 2021, filed 16 Aug 2021.